Ignite Creation Date:
2025-12-26 @ 11:11 PM
Ignite Modification Date:
2025-12-26 @ 11:11 PM
Study NCT ID:
NCT03095612
Status:
TERMINATED
Last Update Posted:
2024-06-13
First Post:
2017-03-23
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)
Sponsor:
University of Texas Southwestern Medical Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-03-22
Start Date Type:
ACTUAL
Primary Completion Date:
2022-11-08
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-03-03
Completion Date Type:
ACTUAL
First Submit Date:
2017-03-23
First Submit QC Date:
None
Study First Post Date:
2017-03-29
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2023-12-21
Results First Submit QC Date:
None
Results First Post Date:
2024-06-13
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-06-12
Last Update Post Date:
2024-06-13
Last Update Post Date Type:
ACTUAL